Biological Chemist by training, I am a senior lecturer in the Division of Pharmacy and Optometry. I have over 25 years of combined experience in academia, industry and SMEs. After qualifying with a PhD (Biological Chemistry, 1988) from University of Essex, I joined Biosensors Group at the Centre for Applied Microbiology Research (CAMR) in Porton Down. I worked on several pathogen and analyte detection projects and developed liposome amplified assays with new triggering mechanisms based on membrane active peptides modified from natural sequences.  I moved to University of Manchester in 1996 as a drug delivery research fellow in the School of Pharmacy & Pharmaceutical Sciences. I made transition to teaching fellow in 2004, specialising in teaching Pharmaceutical analysis and drug development process while also innovating e-learning platform for enabling reliable formative and summative assessments. I became a T&R lecturer in year 2010 and led the development of the year 2 Medicine unit.  

Projects for self-Funded PhD students are available all year round in the drug delivery and nanomedicines area.

Undergraduate modules

Year 1 : The Patient (PHAR 10300)

Year 2 The Medicine  (PHAR 20100) 

Year 3 : BSc Research Projects (PHAR 30500)

Postgraduate: Masters projects (supervision)

Year 2: TBL Lead

BSc, PhD Biological Chemistry  (University of Essex)

1. Senior Fellow of the Higher Education Academy (SFHEA)
2. Member of the Royal Society of Chemistry
3. Member of the Biochemical Society
4. National Governors Association 

Academy Ambassador; The Oldham Academy North

Specialising in solid phase peptide chemistry and lipid vesicles .

Current projects in the following areas:

• Liposomes
• Therapeutic peptides
• Triggers for controlled drug release
• Cytolytic & Cell penetrating peptides  

My research is centred on developing nanomedicines based on synthetic peptides and lipid based formulations. Key focus is not only to steer the delivery of drugs but also sense and utilise the specific biological microenvironment of the diseased state for improved and targeted therapeutic action. My group is also interested in studying peptide/protein therapeutics to identify stability issues which may compromise shelf-life or integrity in biological milieu and solve these through chemical modifications and formulation design.

Some of the current projects includes; delivery of antimicrobials to treat intracellular infections such as TB,  improving the stability of an anti-inflammatory protein through formulation design and chemical modifications for stroke treatment,  design,  synthesis and evaluation  neuropeptide antagonists  as broad spectrum anticancer agents, improving penetration of drugs across biological barriers using cell penetrating peptides as drug carriers.

Projects for self-Funded PhD students are available all year round in the drug delivery and nanomedicines area.